Skip to main content
. Author manuscript; available in PMC: 2011 Apr 21.
Published in final edited form as: Nat Biotechnol. 2010 Jul 2;28(8):839–847. doi: 10.1038/nbt.1663

Figure 2.

Figure 2

Protection of human CD4+ T cells in peripheral blood of HIV-infected mice transplanted with ZFN-modified HSC (a) FACS plots showing human CD4+ and CD8+ T cells in peripheral blood of representative animals from each of three cohorts: uninfected mice previously engrafted with either untreated or ZFN-treated HSC (uninf.), and HIV-1 infected animals previously engrafted with either untreated HSC (neg.) or ZFN-treated (ZFN) HSC, at 4 weeks post-infection. The total number of animals analyzed in each cohort is indicated. Cells were gated on FSC/SSC to remove debris, on human CD45, and a lymphoid gate applied. Percentage of cells in indicated compartments is shown. (b) Ratio of human CD4+ to CD8+ lymphocytes in peripheral blood of individual mice transplanted with untreated (neg.) or ZFN-modified HSC, measured pre-infection, and at 6–8 weeks post-infection. Statistical analysis comparing neg. and ZFN cohorts at each time-point is shown.